Literature DB >> 4010480

Estrogenic effect of tamoxifen and its derivatives on the proliferation of MCF7 human breast tumor cells.

C Sonnenschein, J T Papendorp, A M Soto.   

Abstract

Cloned human MCF-7 breast tumor cells were prevented from proliferating when grown in charcoal-dextran stripped human female serum (CDFHS)-supplemented media (40% and 10%); this inhibition was maximally cancelled by estradiol-17, cisTamoxifen, and Metabolite E, whereas Tamoxifen, N-desmethylTamoxifen and Metabolite Y only partially blocked the inhibitory effect of CDFHS. The efficiency of this reversing effect was estradiol-17 greater than Metabolite E greater than cisTAM greater than OHTAM greater than TAM = Metabolite Y. CDFHS at 2% allowed for near maximal cell yield; estradiol-17 at concentrations above 3 X 10(-10) M inhibited cell proliferation whereas at lower concentrations was ineffective. All the triphenylethylenes tested at 2% CDFHS were toxic above 3 X 10(-7) M; beyond these concentrations, these drugs did not significantly affect the cell yield. The proliferative properties of E2 and these triphenylethylenes do not directly correlate with their binding affinities to the intracellular estrophilins. Finally, the control of the proliferation of C7MCF7-173 cells appears to be affected by the interaction among a) estradiol-17 or the triphenylethylenes, b) a specific blood-borne inhibitor of the proliferation of estrogen-sensitive cells (estrocolyones), and c) an inhibitor "receptor"-like structure in these target cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4010480     DOI: 10.1016/0024-3205(85)90510-7

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  2 in total

1.  Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells.

Authors:  R Poulin; Y Merand; D Poirier; C Levesque; J M Dufour; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1989-10       Impact factor: 4.872

2.  Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen.

Authors:  M Berry; D Metzger; P Chambon
Journal:  EMBO J       Date:  1990-09       Impact factor: 11.598

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.